Literature DB >> 1615764

HLA antigens and intracranial aneurysms.

M Ryba1, P Grieb, I Podobińska, K Iwańska, M Pastuszko, A Górski.   

Abstract

The frequencies of the HLA-A, -B and -DR were determined in a group of 59 transplant donors who died from subarachnoid haemorrhage within three days following the rupture of intracranial aneurysm (the SAH group) and compared with those of a control group consisting of 389 donors who died from other causes. The only significant difference was in the increased frequency in the SAH group of non-typed ("empty")-DR loci in association with the DR7 phenotype. The most probable explanation of this finding is that in the SAH group the frequency of DR7 homozygotes is several times higher than in the general population, and that bearing the DR7 allele in homozygotic form is associated with a very high risk of developing potentially fatal intracranial aneurysmal haemorrhage.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1615764     DOI: 10.1007/bf01541246

Source DB:  PubMed          Journal:  Acta Neurochir (Wien)        ISSN: 0001-6268            Impact factor:   2.216


  16 in total

1.  The familial occurrence of berry aneurysm.

Authors:  P J Beumont
Journal:  J Neurol Neurosurg Psychiatry       Date:  1968-08       Impact factor: 10.154

2.  Genetic markers in patients with intracranial aneurysms.

Authors:  O Norrgård; G Beckman; L Beckman; B Cedergren; H Fodstad; K A Angquist
Journal:  Hum Hered       Date:  1987       Impact factor: 0.444

Review 3.  HLA and disease 1982--a survey.

Authors:  A Svejgaard; P Platz; L P Ryder
Journal:  Immunol Rev       Date:  1983       Impact factor: 12.988

4.  Immunological reaction against the aging human subarachnoid erythrocyte. A model for the onset of cerebral vasospasm after subarachnoid hemorrhage.

Authors:  J W Peterson; B D Kwun; A Teramura; J D Hackett; J A Morgan; S Nishizawa; T Bun; N T Zervas
Journal:  J Neurosurg       Date:  1989-11       Impact factor: 5.115

5.  Familial intracranial aneurysms. Six cases among 13 siblings.

Authors:  J L Fox; J P Ko
Journal:  J Neurosurg       Date:  1980-04       Impact factor: 5.115

6.  Immune complexes and complement activation following rupture of intracranial saccular aneurysms.

Authors:  J R Ostergaard; B O Kristensen; S E Svehag; B Teisner; T Miletic
Journal:  J Neurosurg       Date:  1987-06       Impact factor: 5.115

7.  Is the vasospasm following subarachnoidal hemorrhage an immunoreactive disease?

Authors:  L Pellettieri; C A Carlson; L Lindholm
Journal:  Experientia       Date:  1981-11-15

Review 8.  Origin, growth, and rupture of saccular aneurysms: a review.

Authors:  L N Sekhar; R C Heros
Journal:  Neurosurgery       Date:  1981-02       Impact factor: 4.654

9.  Family study of the major histocompatibility complex in patients with systemic lupus erythematosus: importance of null alleles of C4A and C4B in determining disease susceptibility.

Authors:  A H Fielder; M J Walport; J R Batchelor; R I Rynes; C M Black; I A Dodi; G R Hughes
Journal:  Br Med J (Clin Res Ed)       Date:  1983-02-05

10.  HLA antigens and complement types in patients with intracranial saccular aneurysms.

Authors:  J R Ostergaard; G Bruun-Petersen; L U Lamm
Journal:  Tissue Antigens       Date:  1986-09
View more
  3 in total

1.  Gene expression changes: five years after creation of elastase-induced aneurysms.

Authors:  Ramanathan Kadirvel; Yong-Hong Ding; Daying Dai; Debra A Lewis; David F Kallmes
Journal:  J Vasc Interv Radiol       Date:  2011-04-08       Impact factor: 3.464

2.  Impaired in vitro proliferative response of suppressor lymphocytes in patients with subarachnoid haemorrhage from ruptured intracranial aneurysm.

Authors:  M Ryba; P Grieb; M Pastuszko; B Wegier-Filipiuk; E Mrowiec; J Andrychowski; L Konopka
Journal:  Acta Neurochir (Wien)       Date:  1993       Impact factor: 2.216

3.  HLA-type of cerebral vasospasm patients after aneurysmal subarachnoid hemorrhage.

Authors:  J Sakaguchi; M Takeshita; M Kagawa; M Izawa; K Takakura
Journal:  Neurosurg Rev       Date:  1994       Impact factor: 3.042

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.